Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • NHS England agrees funding for life-saving hepatitis C drug

    NHS England has approved an £18.7 million investment in a new drug for the treatment of hepatitis C. Around 500 patients with acute liver failure, and/or awaiting liver transplantation, are expected to benefit from the decision to fund Sofosbuvir.

    17 April 2014 | NHS England (press release)
  • Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1

    If approved, atazanavir sulfate and cobicistat could offer patients living with HIV-1 a single tablet that eliminates the need to take a boosting agent in a separate tablet. Cobicistat is developed by Gilead Sciences, Inc.

    15 April 2014 | Bristol-Myers Squibb press release
  • International Liver Conference: activists demand affordable hepatitis C treatment

    As the 49th International Liver Conference is officially starting, activist held a demonstration in the main hall to raise the issue of access to hepatitis C treatment in low and middle-income countries. Their protest targeted Gilead whose recently-approved direct-acting antiviral, Sovaldi, sells for USD $84,000.

    11 April 2014 | HepCoalition
  • U.S. drug industry group defends price of Gilead hepatitis drug

    The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.

    11 April 2014 | Reuters
  • Gilead Sciences: How serious is the pricing problem?

    There really isn’t much precedent at all for branded companies competing on price in a MAJOR (~double digit) way. Plenty of companies play around with rebates and discounts, but it’s rare that the net price difference between major brands is more than a few percentage points.

    09 April 2014 | Barron's
  • Gilead aims to license hepatitis C drug to 3-4 Indian firms

    Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 developing nations.

    09 April 2014 | Reuters
  • Express Scripts Raises Pressure on Gilead for Drug Price

    Express Scripts Holding Co. (ESRX), a pharmacy benefit manager that handles more than 1 billion prescriptions annually in the U.S., is ratcheting up its effort to force Gilead Sciences Inc. (GILD) to cut the $84,000 price of its new hepatitis C pill Sovaldi.

    08 April 2014 | Bloomberg
  • Global Fund And Tiered Medicines Pricing Under Debate

    The Global Fund to Fight AIDS, Tuberculosis and Malaria has launched an initiative with other agencies aimed at expanding global access to health products such as medicines. But the Fund has had some explaining to do about the initiative, which some say could encompass a plan to allow different prices based on national income levels.

    08 April 2014 | Intellectual Property Watch
  • Costs to public of $84,000 hep C drug ‘outrageous' - Kaiser Permanente

    Kaiser Permanente, the biggest U.S. health maintenance organization, said it is using Gilead Sciences' new hepatitis C drug, Sovaldi, even though its $84,000 treatment price is "outrageous."

    03 April 2014 | Reuters
  • Big Pharma Abandons New Tuberculosis Drug Research

    Three major pharmaceutical companies - AstraZeneca, Johnson & Johnson and Pfizer - have recently delayed or canceled clinical trials for testing tuberculosis (TB) drugs in India and South Africa. Activists say this is symbolic of a trend by Big Pharma to abandon research into diseases that affect poor people.

    02 April 2014 |
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.